H.C. Wainwright Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $8
Opus Genetics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Opus Genetics, Maintains $8 Price Target
Analysts Offer Insights on Healthcare Companies: Opus Genetics (IRD), Tactile Systems Technology (TCMD) and Insmed (INSM)
JonesTrading Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $9
Buy Rating Affirmed for Opus Genetics Amid Promising OPGx-LCA5 Treatment Results and Regulatory Progress
Analysts Offer Insights on Healthcare Companies: Opus Genetics (IRD) and Brainstorm Cell Therapeutics (BCLI)
Analysts' Top Healthcare Picks: Opus Genetics (IRD), Elevation Oncology (ELEV)
Opus Genetics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Opus Genetics, Maintains $8 Price Target
CCORF Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $10
Opus Genetics: Promising Future With Key Data Readouts and Strong Financial Position Justify Buy Rating
JonesTrading Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $9
JonesTrading Maintains Opus Genetics(IRD.US) With Buy Rating, Cuts Target Price to $9
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Opus Genetics (IRD)
Ocuphire Pharma Is Maintained at Buy by Canaccord Genuity
Ocuphire Pharma Analyst Ratings
CCORF Maintains Ocuphire Pharma(OCUP.US) With Buy Rating, Cuts Target Price to $10
Analysts Offer Insights on Healthcare Companies: Ocuphire Pharma (OCUP), Chimerix (CMRX) and Mersana Therapeutics (MRSN)
Analysts Offer Insights on Healthcare Companies: Chimerix (CMRX) and Ocuphire Pharma (OCUP)